Quotes 5-day view Delayed Nasdaq
04/13/2018
04/16/2018
04/17/2018
04/18/2018
04/19/2018
Date
3.81(c)
4.01(c)
4.22(c)
4.11(c)
4.03
Last
116 750
149 430
203 241
83 537
71 279
Volume
-0.78%
+5.25%
+5.24%
-2.61%
-1.95%
Change
Sales 2018
0,07 M
EBIT 2018
-119 M
Net income 2018
-118 M
Debt 2018
-
Yield 2018
-
Sales 2019
0,07 M
EBIT 2019
-134 M
Net income 2019
-133 M
Debt 2019
-
Yield 2019
-
P/E ratio 2018
-
P/E ratio 2019
Capi. / Sales2018
4 922x
Capi. / Sales2019
4 922x
Capitalization
325 M
NantKwest, Inc. is a next generation clinical-stage immunotherapy company, which engages n the development and production of cancer treatment products.Its products are based on its proprietary natural killer (NK) cell line, NK-92.The firm operates through the following geographical segments: United...
Surperformance© ratings of Nantkwest Inc
Trading Rating :
-
Investor Rating :
Latest news on NANTKWEST INC
Sector news : Bio Therapeutic Drugs
Qtime:60
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NANTKWEST INC
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
4
Average target price
3,00 $
Spread / Average Target
-27%
Please enable JavaScript in your browser's settings to use dynamic charts.